Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

canceR agnOstic immUnoTherapy predIctioN blood-tEst

Project description

Predicting patient response to immune checkpoint inhibitors

Cancer is the second leading cause of death globally, with 10 million fatalities in 2020. While seven immune checkpoint inhibitors (ICIs) have been approved, marking a significant advancement, only 10 % to 50 % of patients with advanced cancer respond to them. The unpredictability of outcomes, coupled with severe toxicity rates of 15 % to 60 % and high costs, limits their effectiveness. The EIC-funded ROUTINE project aims to address this challenge by developing an innovative diagnostics platform called PamGene’s IOpener. This platform uses microarray-based kinase activity profiling of immune cells to predict a patient’s response to ICIs from a simple blood draw before treatment begins. By improving response prediction, the project seeks to enhance the use of ICIs across all cancer stages in precision medicine.

Objective

Cancer is the second leading cause of death worldwide, accounting for 10M deaths in 2020. Although 7 Immune Checkpoint Inhibitors (ICI) are approved for different cancer indications and have represented a true breakthrough, only 10-50% of advanced cancer patients respond to the treatment. This unpredictability of results, together with 15-60% severe toxicity rates and high prices are restricting the impact potential of ICIs. Predicting ICI response is critical for fully realizing their potential in treating early-stage tumours and enhancing ICI treatment regimens.

PamGenes IOpener is a ground-breaking in vitro diagnostics testing platform for ICI response prediction. Made possible by PamGenes proprietary microarray-based kinase activity profiling of host immune cells, it can predict a patients response before ICI therapy is started from a simple blood draw. The IOpener aims to revolutionize the precision-medicine sector, enabling the widespread use of ICIs at any cancer stage.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

PAMGENE INTERNATIONAL BV
Net EU contribution
€ 2 500 000,00
Address
WOLVENHOEK 10
5211 HH S HERTOGENBOSCH
Netherlands
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 669 631,25